Get Oseni Online

Oseni is a once-daily prescription tablet that combines alogliptin and pioglitazone. Alogliptin is a DPP-4 inhibitor that helps the pancreas release more insulin after meals by blocking the breakdown of incretin hormones. Pioglitazone is a thiazolidinedione that makes the body's cells more sensitive to insulin. Together, they target blood sugar from two directions.

Oseni is not appropriate for people with type 1 diabetes, diabetic ketoacidosis, symptomatic or New York Heart Association Class III or IV heart failure, active bladder cancer, or a known hypersensitivity to alogliptin or pioglitazone. People with significant liver disease or a history of bladder cancer should discuss risks carefully with their physician.

Common side effects include upper respiratory tract infections, nasopharyngitis, headache, and fluid retention (edema). Pioglitazone can cause or worsen heart failure through fluid retention, so any sudden weight gain, swelling of the legs, or shortness of breath should be reported to a physician promptly.

Oseni alone has a low risk of causing hypoglycemia. However, the risk increases if it is used alongside insulin or a sulfonylurea. If combined with these agents, a dose reduction of the insulin or sulfonylurea may be needed.

The alogliptin component begins working within hours of the first dose, and meaningful HbA1c reductions are typically seen within 4 to 8 weeks. Pioglitazone may take several weeks to months to show its full insulin-sensitizing effect. HbA1c is usually rechecked after 3 months to assess response.

Yes. Regular monitoring of blood glucose and HbA1c is recommended. Liver function tests should be checked if symptoms of liver problems develop. Patients should also be monitored for signs of heart failure, edema, and bone fracture risk, particularly in women, as pioglitazone has been associated with an increased risk of fractures in female patients.

Doctronic uses an AI-guided evaluation to gather your symptoms, medical history, and current medications. A licensed physician then reviews your information, makes a clinical determination, and if appropriate, sends a prescription to your preferred pharmacy. The entire process is HIPAA-compliant and designed to be fast and convenient.

Yes. Doctronic works exclusively with licensed physicians who are board-eligible or board-certified. Every treatment decision is doctor-reviewed and the platform is HIPAA-compliant. Doctronic is available to adults 18 and older in any U.S. state.